A5054375766- Immunotherapy and Immune Responses
- Extracellular vesicles in disease
- Metabolism, Diabetes, and Cancer
- RNA Interference and Gene Delivery
- Adipose Tissue and Metabolism
- Immune cells in cancer
- GDF15 and Related Biomarkers
- Nutrition and Health in Aging
- Adipokines, Inflammation, and Metabolic Diseases
- Algal biology and biofuel production
- Muscle Physiology and Disorders
Daegu Gyeongbuk Institute of Science and Technology
2019-2023
T cell-derived small extracellular vesicles (sEVs) exhibit anti-cancer effects. However, their potential should be reinforced to enhance clinical applicability. Herein, we generated interleukin-2-tethered sEVs (IL2-sEVs) from engineered Jurkat cells expressing IL2 at the plasma membrane via a flexible linker induce an autocrine effect. IL2-sEVs increased ability of CD8+ without affecting regulatory (Treg ) and down-regulated cellular exosomal PD-L1 expression in melanoma cells, causing...
Patients with cancer undergoing chemotherapy experience cachexia anorexia, body weight loss, and the depletion of skeletal muscles adipose tissues. Effective treatment strategies for chemotherapy-induced are scarce. The growth differentiation factor 15 (GDF15)/GDNF family receptor alpha-like (GFRAL)/rearranged during transfection (RET) axis is a critical signalling pathway in cachexia. In this study, we developed fully human GFRAL antagonist antibody investigated whether it inhibits...
Abstract We have developed a novel antibody-drug conjugate (ADC), based on the mAb L100, that selectively targets O-GalNAc-glycoprotein expressed in approximately 20% of all breast cancer. Unlike many ADC programs targeting Breast Cancer, L100 recognizes cancer-specific O-glycosylated versions proteins do not present normal tissues circumventing adverse events from target off tumor binding to healthy tissues. The crystal structure provides insights into its specificity and affinity. exhibits...